Community
OKXICE to launch 24/7 trading in tokenized US securities
By Tommy Anderson
Amgen’s experimental Sjogren’s drug meets late-stage trial goal
Sofia Cheung
Sofia Cheung
Reporter · Fargo, ND
Sofia Cheung is a dedicated community reporter with a focus on social issues affecting the Fargo area. A graduate of North Dakota State University, she has spent the last four years reporting for local networks, ensuring that underrepresented voices are heard.
More from Sofia →Reporter · Wednesday, November 11, 2026 at 1:07 PM · 1 min read
Nov 11 (Reuters) Amgen said on Wednesday its experimental drug showed sustained reduction in disease activity in a late-stage study of patients with Sjogren s disease, an autoimmune condition. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
Up nextOKXICE to launch 24/7 trading in tokenized US securitiesCommunity · 1 min read
